H.C. Wainwright assumed coverage of Larimar Therapeutics with a Buy rating and $10 price target. The company's biologics license application for nomlabofusp later this year is likely to receive priority review, the analyst tells investors in a research note. The firm forecasts a commercial launch of nomlabofusp in 2027 with sales of $47.9M that year, growing to peak annual sales of over $1.1B by 2040.
